European Medicines Agency recommends restricting use of cilostazol-containing medicines

Source: EMA Area: News Following a review of the current evidence, the European Medicines Agency's (EMA) Committee on Medicinal Products for Human Use (CHMP) has recommended that the use of cilostazol in the treatment of intermittent claudication should be restricted with a range of new measures aimed at targeting a patient population in which there are clinical benefits, and at the same time minimising important risks.   The Spanish Agency for Medicines and Health Products (AEMPS) asked the CHMP to carry out a review of cilostazol following a number of reports of serious suspected adverse effects, in particular affecting the heart, as well as cases of serious bleeding.   The EMA has made the following recommendations to healthcare professionals (direct from source):   . Cilostazol should only be used for intermittent claudication when lifestyle changes (including smoking cessation and exercise programmes) and other appropriate interventions alone have not produced ...
Source: NeLM - Cardiovascular Medicine - Category: Cardiology Source Type: news